Joanne Kotsopoulos, PhD, from Women’s College Research Institute in Toronto, Canada, discusses her involvement in a large research team conducting collaborative studies to address important clinical questions related to breast cancer risk in BRCA mutation carriers. The team analyzes various factors, such as oral contraceptive use, tamoxifen for chemoprevention, and hormone replacement therapy (HRT) after oophorectomy. While tamoxifen showed a protective effect in their analysis, the increased breast cancer risk associated with oral contraceptive use in mutation carriers raises questions about the persistence of this risk after discontinuation. Additionally, Dr Kotsopoulos emphasizes the importance of finding safe ways to use HRT after oophorectomy to manage non-cancer outcomes and ensure a good quality of life for these high-risk populations. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.